<SEC-DOCUMENT>0001157523-23-000960.txt : 20230612
<SEC-HEADER>0001157523-23-000960.hdr.sgml : 20230612
<ACCEPTANCE-DATETIME>20230612060036
ACCESSION NUMBER:		0001157523-23-000960
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20230610
FILED AS OF DATE:		20230612
DATE AS OF CHANGE:		20230612

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innate Pharma SA
		CENTRAL INDEX KEY:			0001598599
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39084
		FILM NUMBER:		231007008

	BUSINESS ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009
		BUSINESS PHONE:		33430303030

	MAIL ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Innate Pharma, SA
		DATE OF NAME CHANGE:	20140129
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a53417993.htm
<DESCRIPTION>INNATE PHARMA S.A. 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div style="text-align: center; margin-right: 6.25pt; margin-left: 6.9pt; font-size: 12pt; font-weight: bold;"> <br>
  </div>
  <div style="text-align: center; margin-right: 6.25pt; margin-left: 6.9pt; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">UNITED STATES</div>
  <div style="text-align: center; margin-right: 6.25pt; margin-left: 6.9pt; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
  <div style="text-align: center; margin-right: 198.8pt; margin-left: 199.6pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Washington, D.C. 20549</div>
  <div style="text-align: center; margin-right: 198.8pt; margin-left: 199.6pt; font-size: 12pt; font-weight: bold;"> </div>
  <div style="text-align: center; margin-right: 198.8pt; margin-left: 199.6pt; font-size: 12pt; font-weight: bold;"> <br>
  </div>
  <div style="text-align: center; margin-right: 198.8pt; margin-left: 199.6pt; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">FORM 6-K</div>
  <div>&#160;</div>
  <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.9pt; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</div>
  <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.9pt; font-weight: bold;"> UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
  <div><br>
  </div>
  <div style="text-align: center; margin-right: 163.55pt; margin-left: 163.6pt; font-weight: bold;">Date of report: For the month of June 2023</div>
  <div style="text-align: center; margin-right: 163.55pt; margin-left: 163.6pt; font-weight: bold;">Commission File Number: 001-39084</div>
  <div>&#160;</div>
  <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.75pt; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">Innate Pharma S.A.</div>
  <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.75pt;">(Translation of registrant's name into English)</div>
  <div><br>
  </div>
  <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.75pt; font-weight: bold;">Innate Pharma S.A.</div>
  <div style="text-align: center; margin-right: 6.25pt; margin-left: 6.9pt; font-weight: bold;">117 Avenue de Luminy&#8212;BP 30191</div>
  <div style="text-align: center; margin-right: 6.3pt; margin-left: 6.9pt; font-weight: bold;">13009 Marseille, France</div>
  <div style="text-align: center; margin-right: 6.75pt; margin-left: 2.3pt; font-weight: bold;">+ 33 (0) 4 30 30 30</div>
  <div style="text-align: center; margin-right: 6.3pt; margin-left: 6.9pt;">(Address of principal executive office)</div>
  <div>&#160;</div>
  <div>&#160;</div>
  <div style="margin-right: 56.8pt; margin-left: 5.55pt;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form
    40-F. </div>
  <div style="margin-right: 56.8pt; margin-left: 5.55pt;"> <br>
  </div>
  <div style="margin-right: 56.8pt; margin-left: 5.55pt;">Form 20-F [ X ]<font class="TRGRRTFtoHTMLTab" style="text-indent: 0px; font-size: 6pt;"> &#160; &#160; &#160; &#160; </font>Form 40-F [
    &#160; ]<br>
    <br>
  </div>
  <div style="margin-right: 34.45pt; margin-left: 5.55pt;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
    101(b)(1): [ &#160; ]</div>
  <div>&#160;</div>
  <div style="margin-right: 34.45pt; margin-left: 5.55pt;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
    101(b)(7): [ &#160; ]</div>
  <div style="margin-right: 34.45pt; margin-left: 5.55pt;"> <br>
  </div>
  <div style="margin-right: 34.45pt; margin-left: 5.55pt;"> <br>
  </div>
  <div><br>
  </div>
  <div>
    <div style="text-align: center; color: #000000; font-weight: bold;">INCORPORATION BY REFERENCE</div>
  </div>
  <div>
    <div>&#160;</div>
    <div style="color: #000000;">This Report on Form&#160;6-K&#160;[and Exhibit 99.1 to this Report on Form&#160;6-K]&#160;shall be deemed to be incorporated by reference into the registration
      statement on Form&#160;F-3&#160;(File&#160;No.&#160;333-252074)&#160;of Innate Pharma S.A. (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is furnished, to the extent not superseded by
      documents or reports subsequently filed or furnished.</div>
  </div>
  <div><br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div style="text-align: center; margin-right: 6.25pt; margin-left: 6.9pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">EXHIBIT INDEX</div>
  <div>&#160;</div>
  <div>&#160;
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="z4b581350e9b74260ac50e5620382c46b">

        <tr>
          <td style="width: 10%;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>Exhibit</u></font><font class="TRGRRTFtoHTMLTab" style="text-indent: 0px;"> <br>
            </font></td>
          <td style="width: 90%;"><font style="font-weight: bold; font-family: 'Times New Roman',Times,serif;"><u>Description</u></font></td>
        </tr>
        <tr>
          <td style="width: 10%;">
            <div>&#160;</div>
          </td>
          <td style="width: 90%;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%;"><a href="a53417993_ex991.htm">99.1</a><br>
          </td>
          <td style="width: 90%;"><a href="a53417993_ex991.htm">[Press Release dated June 10, 2023]</a><br>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.75pt; font-weight: bold;">SIGNATURES</div>
  <div><br>
  </div>
  <div style="margin-right: 14.85pt; margin-left: 5.55pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
    be signed on its behalf by the undersigned, thereunto duly authorized.</div>
  <div style="margin-right: 14.85pt; margin-left: 5.55pt;"> <br>
  </div>
  <div>&#160;</div>
  <div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="zcea51dd6668940ad808d4ddefe36397e">

        <tr>
          <td style="width: 50%; font-weight: bold;">
            <div>&#160;</div>
          </td>
          <td style="width: 5%; font-weight: bold;" rowspan="1" colspan="2">INNATE PHARMA S.A.</td>
        </tr>
        <tr>
          <td style="width: 50%;">
            <div>&#160;</div>
          </td>
          <td style="width: 5%;">
            <div>&#160;</div>
          </td>
          <td style="width: 45%;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%;">
            <div>&#160;</div>
          </td>
          <td style="width: 5%;">
            <div>&#160;</div>
          </td>
          <td style="width: 45%;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; padding-bottom: 2px;"><font style="font-size: 8pt;">&#160;<font style="font-size: 10pt;"> Date: June 10, 2023</font></font></td>
          <td style="width: 5%; padding-bottom: 2px;">By:<br>
          </td>
          <td style="width: 45%; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-family: 'Times New Roman',Times,serif;">/s/ Mondher MAHJOUBI</font></td>
        </tr>
        <tr>
          <td style="width: 50%;">
            <div>&#160;</div>
          </td>
          <td style="width: 5%;">Name:<br>
          </td>
          <td style="width: 45%;">Mondher MAHJOUBI</td>
        </tr>
        <tr>
          <td style="width: 50%;">
            <div>&#160;</div>
          </td>
          <td style="width: 5%;">Title:</td>
          <td style="width: 45%;"><font style="font-family: 'Times New Roman',Times,serif;">Chairman of the Executive Board and Chief Executive Officer</font></td>
        </tr>

    </table>
  </div>
  <div style="margin-left: 280.1pt; font-size: 8pt; font-weight: bold;"><br>
  </div>
  <div><br>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a53417993_ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div><font style="font-weight: bold;"> </font>
    <div class="bw-release">
      <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>Innate Pharma Highlights Proprietary Tetra-specific ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> NK Cell Engager IPH6501 at the EHA 2023 Congress</b> </h1>
      <div class="bw-release-subhead">
        <ul style="list-style-type: disc;">
          <b>
            <li> <b><i>IPH6501 is a first-in-class tetra-specific antibody-based natural killer cell engager therapeutic, based on ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> platform, targeting CD20 developed for the treatment of B-cell non-Hodgkin's lymphomas</i></b> </li>
            <li> <b><i>IPH6501 is progressing towards a Phase 1 clinical trial in 2023</i></b> </li>
          </b>
        </ul>
      </div>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p>MARSEILLE, France--(BUSINESS WIRE)--June 10, 2023--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (&#8220;<b>Innate</b>&#8221; or the &#8220;<b>Company</b>&#8221;) today announced that updated preclinical data on its IPH6501 tetra-specific ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (<b>A</b>ntibody-based
            <b>N</b>atural <b>K</b>iller cell <b>E</b>ngager <b>T</b>herapeutics) are presented at the European Hematology Association (EHA) 2023 congress. IPH6501 is a first-in-class CD20-targeting tetra-specific ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> that co-engages two
            activating receptors (NKp46 and CD16), the interleukin-2 receptor (without involvement of the IL-2R&#945; subunit) with a human IL-2 variant and CD20 target antigen on malignant B cells. </p>
          <p> In preclinical settings, IPH6501 was shown to induce NK cell proliferation and to trigger high NK cell cytoxicity against CD20+ target cells in <i>in vitro</i> assays, in <i>ex vivo </i>assays with relapse/refractory (R/R) B-NHL patient
            samples who received at least one prior treatment, as well as in <i>in vivo</i> studies in non-human primates. A surrogate of IPH6501 mediated a potent anti-tumor activity <i>in vivo</i> in CD20+ tumor models in mice. In addition, in <i>ex
              vivo</i> assays with R/R B-NHL patient samples, IPH6501 was shown to be more efficient than a T cell engager targeting CD20. </p>
          <p> <b>Pr. Eric Vivier, PhD, DVM, Chief Scientific Officer at Innate Pharma</b> &#8220;<i>As the lead in this new class of tetra-specific NK-cell engager</i>, <i>IPH6501 represents an innovative option for the treatment of R/R B-cell non-Hodgkin&#8217;s
              lymphomas after multiple lines of treatment, who are still in need of therapies. By providing proliferation and activation signals targeted to NK cells, the tetra-specific NK Cell Engager based on our ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> platform leverages the
              advantages of harnessing NK cell effector functions against cancer cells. With a low systemic cytokine release profile, IPH6501 represents a promising alternative strategy to T cell therapies. IPH6501 continues to progress towards a Phase 1
              clinical trial and we look forward to share further updates on other ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> assets as they enter clinic</i>.&#8221; </p>
          <p> <b>About ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup></b> </p>
          <p> ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is Innate&#8217;s proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer. This fit-for-purpose technology is creating an entirely new class of
            molecules to induce synthetic immunity against cancer. </p>
          <p> Innate&#8217;s latest innovation, the tetra-specific ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, is the first NK cell engager technology to engage activating receptors (NKp46 and CD16), a tumor antigen and the interleukin-2 receptor (via an non-alpha IL-2 variant, IL-2v)
            via a single molecule. By providing proliferation and activation signals targeted to NK cells, tetra-specific ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> leverages the advantages of harnessing NK cell effector functions against cancer cells. </p>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> <b>About Innate Pharma</b> </p>
          <p> Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (<b>A</b>ntibody-based
            <b>NK</b> cell <b>E</b>ngager <b>T</b>herapeutics) proprietary platform. </p>
          <p> Innate&#8217;s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>
            multi-specific NK cell engagers to address multiple tumor types. </p>
          <p> Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. </p>
          <p> Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. </p>
          <p> Learn more about Innate Pharma at www.innate-pharma.com and follow us on Twitter and LinkedIn. </p>
          <p> <b>Information about Innate Pharma shares</b> </p>
          <table cellspacing="0" id="z879e6ed5a32a472193d665a5284d0dca" style="margin-bottom: 10px;margin-left: 0px; margin-right: auto;width: 100%; font-size: 10pt;">

              <tr>
                <td colspan="1" rowspan="1" style="padding-left: 0px;width: 31%;vertical-align: bottom;">
                  <p style="text-align: left;margin-bottom: 0px; margin-top: 0px;"> <b>ISIN code</b> </p>
                </td>
                <td colspan="1" rowspan="1" style="padding-left: 0px;width: 69%;vertical-align: bottom;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> FR0010331421 </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="padding-left: 0px;width: 31%;vertical-align: bottom;">
                  <p style="text-align: left;margin-bottom: 0px; margin-top: 0px;"> <b>Ticker code</b> </p>
                </td>
                <td colspan="1" rowspan="1" style="padding-left: 0px;width: 69%;vertical-align: bottom;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> Euronext: IPH Nasdaq: IPHA </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="padding-left: 0px;width: 31%;vertical-align: bottom;">
                  <p style="text-align: left;margin-bottom: 0px; margin-top: 0px;"> <b>LEI</b> </p>
                </td>
                <td colspan="1" rowspan="1" style="padding-left: 0px;width: 69%;vertical-align: bottom;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> 9695002Y8420ZB8HJE29 </p>
                </td>
              </tr>

          </table>
          <p> <b>Disclaimer on forward-looking information and risk factors</b> </p>
          <p> This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including &#8220;believe,&#8221; &#8220;potential,&#8221; &#8220;expect&#8221; and &#8220;will&#8221; and
            similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which
            could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results
            from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company&#8217;s commercialization efforts and the Company&#8217;s continued ability to raise capital to fund
            its development. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please
            refer to the Risk Factors (&#8220;Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (&#8220;AMF&#8221;), which is available on the AMF website http://www.amf-france.org or on Innate Pharma&#8217;s
            website, and public filings and reports filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), including the Company&#8217;s Annual Report on Form 20-F for the year ended December 31, 2022, and subsequent filings and reports filed with the
            AMF or SEC, or otherwise made public, by the Company. </p>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. </p>
        </div>
        <div class="bw-release-contact">
          <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
          <p> <b><u>Investors</u></b> </p>
          <p> <b>I</b><b>nnate Pharma </b><br>
            Henry Wheeler <br>
            Tel.: +33 (0)4 84 90 32 88 <br>
            Henry.wheeler@innate-pharma.fr </p>
          <p> <b><u>Media Relations</u></b> </p>
          <p> <b>N</b><b>ewCap </b><br>
            Arthur Rouill&#233; <br>
            Tel.: +33 (0)1 44 71 00 15 <br>
            innate@newcap.eu </p>
        </div>
      </div>
    </div>
    <font style="font-weight: bold;"> </font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
